1. Home
  2. LADR vs ZYME Comparison

LADR vs ZYME Comparison

Compare LADR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LADR
  • ZYME
  • Stock Information
  • Founded
  • LADR 2008
  • ZYME 2003
  • Country
  • LADR United States
  • ZYME United States
  • Employees
  • LADR N/A
  • ZYME N/A
  • Industry
  • LADR Real Estate Investment Trusts
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • LADR Real Estate
  • ZYME Health Care
  • Exchange
  • LADR Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • LADR 1.5B
  • ZYME 1.2B
  • IPO Year
  • LADR 2014
  • ZYME 2017
  • Fundamental
  • Price
  • LADR $10.59
  • ZYME $16.56
  • Analyst Decision
  • LADR Buy
  • ZYME Buy
  • Analyst Count
  • LADR 2
  • ZYME 7
  • Target Price
  • LADR $12.75
  • ZYME $20.00
  • AVG Volume (30 Days)
  • LADR 737.6K
  • ZYME 648.0K
  • Earning Date
  • LADR 10-23-2025
  • ZYME 10-30-2025
  • Dividend Yield
  • LADR 8.70%
  • ZYME N/A
  • EPS Growth
  • LADR N/A
  • ZYME N/A
  • EPS
  • LADR 0.70
  • ZYME N/A
  • Revenue
  • LADR $243,794,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • LADR $2.72
  • ZYME $107.76
  • Revenue Next Year
  • LADR $10.00
  • ZYME $2.35
  • P/E Ratio
  • LADR $15.12
  • ZYME N/A
  • Revenue Growth
  • LADR N/A
  • ZYME 95.94
  • 52 Week Low
  • LADR $9.68
  • ZYME $9.03
  • 52 Week High
  • LADR $12.10
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • LADR 31.80
  • ZYME 58.74
  • Support Level
  • LADR $10.66
  • ZYME $16.20
  • Resistance Level
  • LADR $11.47
  • ZYME $17.40
  • Average True Range (ATR)
  • LADR 0.15
  • ZYME 0.55
  • MACD
  • LADR -0.10
  • ZYME -0.08
  • Stochastic Oscillator
  • LADR 17.33
  • ZYME 43.26

About LADR Ladder Capital Corp

Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: